利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.049 秒)

    Triazole derivative and use thereof
    6.
    发明授权
    Triazole derivative and use thereof 失效
    三唑衍生物及其用途

    公开(公告)号：US07803822B2

    公开(公告)日：2010-09-28

    申请号：US11887936

    申请日：2006-04-06

    申请人： Keiji Kubo ,  Mamoru Tobisu ,  Eiji Honda ,  Takahiko Taniguchi ,  Yoshiyuki Fukase ,  Masaki Kawamura ,  Masaharu Nakayama

    发明人： Keiji Kubo ,  Mamoru Tobisu ,  Eiji Honda ,  Takahiko Taniguchi ,  Yoshiyuki Fukase ,  Masaki Kawamura ,  Masaharu Nakayama

    IPC分类号： A61K31/41 ,  C07D249/00

    CPC分类号： C07D249/06 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D411/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

    摘要： The present invention relates to a thrombin receptor antagonist containing a compound represented by the formula (I) wherein R1a, R1b and R2 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted alkoxy, R3 is a group represented by the formula —NHCOR4, —NHSO2R5, —NHCON(R6a)(R6b), —NHCOOR7 or —CONHR8 wherein R4, R5, R6a, R6b, R7 and R8 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like), ring A is monocyclic aromatic ring optionally further having substituent(s), R1a and R1b are optionally bonded to each other to form an optionally substituted nitrogen-containing non-aromatic heterocycle, or a salt thereof or a prodrug thereof. The thrombin receptor antagonist of the present invention has a thrombin receptor (particularly PAR-1) antagonistic action and is useful for the prophylaxis or treatment of PAR-1 mediated pathological condition or disease.

    摘要翻译： 本发明涉及含有式（I）表示的化合物的凝血酶受体拮抗剂，其中R1a，R1b和R2各自为氢原子，任选取代的烃基，任选取代的杂环基或任选取代的烷氧基，R 3 是由式-NHCOR4，-NHSO2R5，-NHCON（R6a）（R6b），-NHCOOR7或-CONHR8表示的基团，其中R4，R5，R6a，R6b，R7和R8各自为氢原子，任选取代的烃基 ，任选取代的杂环基等），环A是任选进一步具有取代基的单环芳环，R 1a和R 1b任选地彼此键合以形成任选取代的含氮非芳族杂环或盐 或其前药。 本发明的凝血酶受体拮抗剂具有凝血酶受体（特别是PAR-1）拮抗作用，可用于预防或治疗PAR-1介导的病理状态或疾病。

    Triazole Derivative and Use Thereof
    7.
    发明申请
    Triazole Derivative and Use Thereof 失效
    三唑衍生物及其用途

    公开(公告)号：US20090105253A1

    公开(公告)日：2009-04-23

    申请号：US11887936

    申请日：2006-04-06

    申请人： Keiji Kubo ,  Mamoru Tobisu ,  Eiji Honda ,  Takahiko Taniguchi ,  Yoshiyuki Fukase ,  Masaki Kawamura ,  Masaharu Nakayama

    发明人： Keiji Kubo ,  Mamoru Tobisu ,  Eiji Honda ,  Takahiko Taniguchi ,  Yoshiyuki Fukase ,  Masaki Kawamura ,  Masaharu Nakayama

    IPC分类号： A61K31/5377 ,  C07D249/06 ,  C07D413/12 ,  A61K31/4192

    CPC分类号： C07D249/06 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D411/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

    摘要： The present invention relates to a thrombin receptor antagonist containing a compound represented by the formula (I) wherein R1a, R1b and R2 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted alkoxy, R3 is a group represented by the formula —NHCOR4, —NHSO2R5, —NHCON(R6a)(R6b), —NHCOOR7 or —CONHR8 wherein R4, R5, R6a, R6b, R7 and R8 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like), ring A is monocyclic aromatic ring optionally further having substituent(s), R1a and R1b are optionally bonded to each other to form an optionally substituted nitrogen-containing non-aromatic heterocycle, or a salt thereof or a prodrug thereof. The thrombin receptor antagonist of the present invention has a thrombin receptor (particularly PAR-1) antagonistic action and is useful for the prophylaxis or treatment of PAR-1 mediated pathological condition or disease.

    摘要翻译： 本发明涉及含有式（I）表示的化合物的凝血酶受体拮抗剂，其中R1a，R1b和R2各自为氢原子，任选取代的烃基，任选取代的杂环基或任选取代的烷氧基，R 3 是由式-NHCOR4，-NHSO2R5，-NHCON（R6a）（R6b），-NHCOOR7或-CONHR8表示的基团，其中R4，R5，R6a，R6b，R7和R8各自为氢原子，任选取代的烃基 ，任选取代的杂环基等），环A是任选进一步具有取代基的单环芳环，R 1a和R 1b任选地彼此键合以形成任选取代的含氮非芳族杂环，或盐 或其前药。 本发明的凝血酶受体拮抗剂具有凝血酶受体（特别是PAR-1）拮抗作用，可用于预防或治疗PAR-1介导的病理状态或疾病。